Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Modalis Therapeutics Corporation ( (JP:4883) ) is now available.
Modalis Therapeutics Corporation has been recognized as a top eight finalist in the XPRIZE Healthspan FSHD Bonus Prize competition, receiving $250,000 in research funds. This accolade highlights Modalis’ innovative approach to treating Facioscapulohumeral muscular dystrophy (FSHD) using their CRISPR-GNDM® technology. The recognition not only validates Modalis’ vision of developing treatments for incurable diseases but also positions the company for potential collaborations with global research institutions, enhancing its industry standing.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a pioneering company in the biotechnology industry, focusing on developing precision genetic medicines for rare genetic diseases. Utilizing its proprietary CRISPR-GNDM® epigenome editing technology, Modalis aims to create therapies for orphan genetic diseases by modulating gene expression without altering DNA sequences. The company is headquartered in Tokyo, with facilities in Waltham, Massachusetts, and is listed on the Tokyo Stock Exchange’s Growth market.
Average Trading Volume: 1,879,842
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.47B
For an in-depth examination of 4883 stock, go to TipRanks’ Stock Analysis page.